An analysis of polymorphisms within the Wnt signaling pathway in relation to ovarian cancer risk in a Polish population

Molecular Diagnosis and Therapy

Volumn 18, Issue 1, 2014, Pages 85-91

  Mostowska, Adrianna ^a   Pawlik, Piotr ^a   Sajdak, Stefan ^a   Markowska, Janina ^a   Pawałowska, Monika ^a   Lianeri, Margarita ^a   Jagodzinski, Paweł P ^a  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; APC GENE; ARTICLE; AXIN2 GENE; CANCER RISK; CONTROLLED STUDY; CTNNB1 GENE; DOMINANT INHERITANCE; FEMALE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPING TECHNIQUE; HIGH RESOLUTION MELTING ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; OVARY CANCER; POLAND; POLYMERASE CHAIN REACTION SYSTEM; POPULATION GENETICS; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RESTRICTION MAPPING; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR GENE; TUMOR SUPPRESSOR GENE; WNT SIGNALING PATHWAY;

ADENOMATOUS POLYPOSIS COLI PROTEIN; AGED; BRCA1 PROTEIN; BRCA2 PROTEIN; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; POLAND; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS; WNT SIGNALING PATHWAY;

EID: 84893316426     PISSN: 11771062     EISSN: 11792000     Source Type: Journal    
DOI: 10.1007/s40291-013-0059-y     Document Type: Article

References (45)

1. Ferlay J, Autier P, Boniol M, et al. Estimates of the cancer incidence and mortality in Europe in 2006. Ann Oncol. 2007;18(3):581-92.
2. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58(2):71-96.
3. Sueblinvong T, Carney ME. Current understanding of risk factors for ovarian cancer. Curr Treat Options Oncol. 2009;10(1-2):67-81.
4. Berchuck A, Schildkraut JM, Marks JR, et al. Managing hereditary ovarian cancer risk. Cancer. 1999;86(11 Suppl):2517-24.
5. Frank TS, Manley SA, Olopade OI, et al. Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk. J Clin Oncol. 1998;16(7):2417-25.
6. Holschneider CH, Berek JS. Ovarian cancer: epidemiology, biology, and prognostic factors. Semin Surg Oncol. 2000;19(1):3-10.
7. Choi YP, Shim HS, Gao MQ, et al. Molecular portraits of intratumoral heterogeneity in human ovarian cancer. Cancer Lett. 2011;307(1):62-71.
8. Bitler BG, Nicodemus JP, Li H, et al. Wnt5a suppresses epithelial ovarian cancer by promoting cellular senescence R. Cancer Res. 2011;71(19):6184-94.
9. Chien AJ, Conrad WH, Moon RT. A Wnt survival guide: from flies to human disease. J Invest Dermatol. 2009;129(7):1614-27.
10. Hsieh M, Johnson MA, Greenberg NM, et al. Regulated expression of Wnts and Frizzleds at specific stages of follicular development in the rodent ovary. Endocrinology. 2002;143(3):898-908.
11. Vainio S, Heikkila M, Kispert A, et al. Female development in mammals is regulated by Wnt-4 signalling. Nature. 1999;397(6718):405-9.
12. Novak A, Dedhar S. Signaling through beta-catenin and Lef/Tcf. Cell Mol Life Sci. 1999;56(5-6):523-37.
13. Herr P, Hausmann G, Basler K. WNT secretion and signalling in human disease. Trends Mol Med. 2012;18(8):483-93.
14. Gatcliffe TA, Monk BJ, Planutis K, et al. Wnt signaling in ovarian tumorigenesis. Int J Gynecol Cancer. 2008;18(5):954-62.
15. Sagae S, Kobayashi K, Nishioka Y, et al. Mutational analysis of beta-catenin gene in Japanese ovarian carcinomas: frequent mutations in endometrioid carcinomas. Jpn J Cancer Res. 1999;90(5):510-5.
16. Saegusa M, Okayasu I. Frequent nuclear beta-catenin accumulation and associated mutations in endometrioid-type endometrial and ovarian carcinomas with squamous differentiation. J Pathol. 2001;194(1):59-67.
17. Wu R, Zhai Y, Fearon ER, et al. Diverse mechanisms of beta-catenin deregulation in ovarian endometrioid adenocarcinomas. Cancer Res. 2001;61(22):8247-55.
18. Polakis P. Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012;4:a008052.
19. Wang S, Tian Y, Wu D, et al. Genetic variation of CTNNB1 gene is associated with susceptibility and prognosis of gastric cancer in a Chinese population. Mutagenesis. 2012;27(6):623-30.
20. Starker LF, Fonseca A, Akerström G, et al. Evidence of a stabilizing mutation of β-catenin encoded by CTNNB1 exon 3 in a large series of sporadic parathyroid adenomas. Endocrine. 2012;42(3):612-5.
21. Yoshie T, Nishiumi S, Izumi Y, et al. Regulation of the metabolite profile by an APC gene mutation in colorectal cancer. Cancer Sci. 2012;103(6):1010-21.
22. Erbilgin Y, Ng OH, Mavi N, et al. Genetic alterations in members of the Wnt pathway in acute leukemia. Leuk Lymphoma. 2012;53(3):508-10.
23. Sercan Z, Pehlivan M, Gokturk D, et al. Beta-catenin mutations are not observed in chronic myeloid leukemia. Tumori. 2009;95(6):836-9.
24. Wang X, Goode EL, Fredericksen ZS, et al. Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer. Cancer Epidemiol Biomarkers Prev. 2008;17(8):2101-8.
25. Laken SJ, Peterson GM, Gruber SB, et al. Familial colorectal cancer in Ashkenazim due to a hypermutable tract in APC. Nat Genet. 1997;17(1):79-83.
26. Pinarbasi E, Gunes EG, Pinarbasi H, et al. AXIN2 polymorphism and its association with prostate cancer in a Turkish population. Med Oncol. 2011;28(4):1373-8.
27. Gunes EG, Pinarbasi E, Pinarbasi H, et al. Strong association between lung cancer and the AXIN2 polymorphism. Mol Med Report. 2009;2(6):1029-35.
28. Gunes EG, Pinarbasi E, Pinarbasi H. AXIN2 polymorphism and its association with astrocytoma in a Turkish population. Mol Med Report. 2010;3(4):705-9.
29. Kanzaki H, Ouchida M, Hanafusa H, et al. Single nucleotide polymorphism of the AXIN2 gene is preferentially associated with human lung cancer risk in a Japanese population. Int J Mol Med. 2006;18(2):279-84.
30. Wong HL, Peters U, Hayes RB, et al. Polymorphisms in the adenomatous polyposis coli (APC) gene and advanced colorectal adenoma risk. Eur J Cancer. 2010;46(13):2457-66.
31. Guerreiro CS, Cravo ML, Brito M, et al. The D1822V APC polymorphism interacts with fat, calcium, and fiber intakes in modulating the risk of colorectal cancer in Portuguese persons. Am J Clin Nutr. 2007;85(6):1592-7.
32. Wu R, Hendrix-Lucas N, Kuick R, et al. Mouse model of human ovarian endometrioid adenocarcinoma based on somatic defects in the Wnt/beta-catenin and PI3K/Pten signaling pathways. Cancer Cell. 2007;11(4):321-33.
33. Nyholt DR. A simple correction for multiple testing for SNPs in linkage disequilibrium with each other. Am J Hum Genet. 2004;74(4):765-9.
34. Dudbridge F. Likelihood-based association analysis for nuclear families and unrelated subjects with missing genotype data. Hum Hered. 2008;66(2):87-98.
35. Hahn LW, Ritchie MD, Moore JH. Multifactor dimensionality reduction software for detecting gene-gene and gene-environment interactions. Bioinformatics. 2003;19(3):376-82.
36. Abrahamson J, Moslehi R, Vesprini D, et al. No association of the I1307K APC allele with ovarian cancer risk in Ashkenazi Jews. Cancer Res. 1998;58(14):2919-22.
37. Gershoni-Baruch R, Patael Y, Dagan, et al. Association of the I1307K APC mutation with hereditary and sporadic breast/ovarian cancer: more questions than answers. Br J Cancer. 2000;83(2):153-5.
38. Wright K, Wilson P, Morland S, et al. Beta-catenin mutation and expression analysis in ovarian cancer: exon 3 mutations and nuclear translocation in 16% of endometrioid tumours. Int J Cancer. 1999;82(5):625-9.
39. Sarrió D, Moreno-Bueno G, Sánchez-Estévez C, et al. High frequency of beta-catenin mutations in borderline endometrioid tumours of the ovary. Expression of cadherins and catenins correlates with distinct histologic types of ovarian carcinomas. Hum Pathol. 2006;37(5):1042-9.
40. Eklof Spink K, Fridman SG, Weis WI. Molecular mechanisms of beta-catenin recognition by adenomatous polyposis coli revealed by the structure of an APC-beta-catenin complex. EMBO J. 2001;20(22):6203-12.
41. Nakamura T, Hamada F, Ishidate T, et al. Axin, an inhibitor of the Wnt signalling pathway, interacts with beta-catenin, GSK-3 beta and APC and reduces the beta-catenin level. Genes Cells. 1998;3(6):395-403.
42. Notaridou M, Quaye L, Dafou D, et al. Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. Int J Cancer. 2011;128(9):2063-74.
43. Song H, Ramus SJ, Tyrer J, et al. A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nat Genet. 2009;41(9):996-1000.
44. Goode EL, Chenevix-Trench G, Song H, et al. A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nat Genet. 2010;42(10):874-9.
45. Bolton KL, Tyrer J, Song H, et al. Common variants at 19p13 are associated with susceptibility to ovarian cancer. Nat Genet. 2010;42(10):880-4.